A short course of immunotherapy given before surgery eliminated detectable colon cancer in a majority of patients whose ...

Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In the majority of these patients, as the cancer advances it metastasizes to ...

Experts discuss additional factors considered when determining the most effective sequence of therapies for metastatic colorectal cancer, including fruquintinib, regorafenib, and trifluridine + ...

Advanced colorectal cancer presents significant clinical challenges owing to its propensity for metastatic dissemination and the development of chemoresistance. Contemporary management strategies ...

Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial ...

Colorectal cancer is the fourth-most-common cancer in the U.S. and the second deadliest. One in 5 patients is diagnosed with metastatic disease, meaning the colorectal cancer has spread beyond the ...

The use of neoadjuvant chemotherapy failed to improve disease-free survival (DFS) over upfront surgery in patients with locally advanced colon cancer, a phase III randomized trial showed. Among 248 ...

Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In the majority of these patients, as the cancer advances it metastasizes to ...

Researchers have developed and internally validated a simple score using clinical factors that can help estimate the likelihood of advanced colorectal neoplasia in adults younger than age 45 years.

Colorectal cancer remains the third most commonly diagnosed cancer in both men and women in the United States, with approximately 153,000 new cases expected this year alone. While overall rates have ...